Medical Device Innovation Consortium Launches Initiative to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics

MDIC | August 23, 2022 | Read time : 04:00 min

Medical Device

The Medical Device Innovation Consortium formally launched its Somatic Reference Samples Initiative with a pilot project to improve the validation and regulatory review process for cancer diagnostics based on next generation sequencing.

MDIC will lead a collaboration with the U.S. Food and Drug Administration the National Institute of Standards and Technology, National Institutes of Health and industry stakeholders to manufacture, validate, and distribute SRSs to simplify and support validation of NGS-based cancer diagnostics. The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators.

NGS is a powerful technology enabling breakthroughs in diagnostics and ultimately therapeutics. These diagnostic tests need to be validated for accurate clinical use, and reference samples are essential to the validation process. But well-characterized and widely accepted reference materials do not exist for NGS-based diagnostics, complicating the development and validation process. Through the MDIC SRS Initiative, we are developing reference samples and data sets that can be used globally by test developers and regulators to bring more consistency to NGS-based cancer diagnostic development, increasing the confidence and accuracy of these tests, which will ultimately lead to more accuracy in diagnosis and treatment for patients.”

Andrew Fish, President and CEO, MDIC

“There is a need for appropriately consented, highly characterized, and broadly available reference materials that may improve the accuracy, reliability, and transparency of NGS-based oncology tests and support the generation of validation data for use in regulatory submissions. The reference samples and datasets being created by the MDIC Somatic Reference Samples Initiative can help fulfill this need,” said Wendy Rubinstein, MD, PhD, Director, Personalized Medicine, Center for Devices and Radiological Health, U.S. Food and Drug Administration.

Horizon Discovery, a PerkinElmer company, is conducting the development and manufacture of these reference samples. The goal of this pilot project is to individually engineer 10 gene variants clinically associated with cancer into a highly characterized human cell line – GM24385 using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology resulting in ten edited human cell lines, each containing one gene variant clinically associated with one or more specific cancers. The cell lines, containing confirmed sequences, will be combined and available in FFPE format. The fully characterized reference samples will be commercially available to the end users from Horizon and the characterization data will be accessible through public databases, including precisionFDA, an FDA-sponsored site for data information, sequencing, and bioinformatics.

NIST’s involvement in this work is to foster understanding.* “As our collaboration validates the MDIC SRS samples, we will also learn and build best practices to improve the efficiency and sustainability of reference sample validation and dataset generation in general. This project is a major step in the development and optimization of new sequencing technologies and the translation of DNA sequencing to clinical applications for diagnosing and treating cancer,” said Justin Zook, PhD, Co-Leader, Biomarker and Genomic Sciences Group, National Institute of Standards and Technology.

MDIC’s SRS project began as a working group in 2018, representing more than forty stakeholders with a mission to address the gap in reference material for NGS-based diagnostic tests. The initial output of this working group, MDIC’s SRS Landscape Analysis, published in 2019, was a comprehensive catalog of existing clinically relevant cancer variants and available reference samples. Based on the unmet needs discovered through the SRS Landscape Analysis, the SRS Initiative has prioritized a subset of ten variants to be engineered into reference samples for the pilot project. In addition to the utility of these samples in development, validation, and regulatory review, these samples potentially have value in reimbursement decisions, post-market monitoring and informing the path forward for addition SRS.

The work in the SRS Initiative is funded in part by the Gordon and Betty Moore Foundation the National Philanthropic Trust, Illumina, and Quidel.

Affiliation with a commercial product does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose.

About MDIC
Founded in 2012, the Medical Device Innovation Consortium is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to transform health care into human care. Collaborating with our partners to advance science, we enable transformational medical technology to shape the world we want to live in and make that world possible by shortening the path from innovation to safety to access. 


Seton Medical Center Hays: Drug Classes and Common Side Effects.


Seton Medical Center Hays: Drug Classes and Common Side Effects.

Related News


Radius XR a new fashion-forward wearable technology brand brings together multimodal diagnostics practice management and patient engagement

Radius XR | October 03, 2022

IrisVision co-founder and CEO Ammad Khan today introduced a new company, Radius XR, to coincide with the opening of the American Academy of Ophthalmology 2022 meeting in Chicago. Radius XR builds on the therapeutic legacy of IrisVision by introducing diagnostic capability to the proprietary VR/AR assistive device. After the CES Award-winning 2017 launch of IrisVision, which has helped thousands of legally blind individuals see again, the company sought to leverage its core technology to benefit the eyecare industry by creating a patient-guided exam process that makes it easier and more affordable to diagnose a range of vision problems that are pervasive in the U.S. More than 32 million Americans aged 18+ are affected by vision loss, according to the IPUMS National Health Interview Survey1. Using a single Radius XR headset, patients can self-perform a range of vision tests that are clinically equivalent to gold standard exams. The exams currently performed with the Radius XR testing platform are Visual Field, Visual Acuity, Contrast Sensitivity, Amsler Grid, and Color Scheme. Development is ongoing. The shift to patient-guided testing enhances eyecare practice workflow and enables a single technician to administer several test sessions concurrently, doubling patient capacity. The fashion-forward design of Radius XR is a significant leap forward in wearable devices, with the look and feel of a pair of fashionable sunglasses. Radius XR is the industry’s lightest wearable device, weighing just under 6 oz., and features all-day battery life. The small, lightweight design overcomes the challenges of expensive and bulky legacy devices that force patients to sit in uncomfortable positions for testing. Exams can be conducted beyond exam lanes, allowing a patient’s exam in nontraditional spaces like waiting rooms, remote offices, and lobbies. With Radius XR, opportunities for greater accessibility and care are boundless. A breakthrough feature of the Radius XR platform is the immersive educational media library that can be tailored to each patient. This content is configured by each practice to display at an appropriate time during the exam experience automatically, eliminating the repetitive, time-consuming task of providing patients with educational information about their vision challenges while ensuring relevant information is consistently presented. The platform includes a Business Suite of management tools that streamline patient check-in, enable staff to customize the experience for multiple patients, and make it easier for eyecare professionals to manage business aspects critical to their practice's ongoing success. Trefethen named Radius XR CMO The launch of Radius XR is guided by John Trefethen, who joins the company as Chief Marketing Officer. Trefethen previously served in leadership roles at several medical device companies, including industry giants Zeiss Medical Technology and Topcon Healthcare. “Early diagnosis is the key to treating many conditions that can lead to vision loss. We believe a testing platform that combines a comfortable size with an engaging, immersive experience makes patients more likely to seek testing — and to be re-tested more frequently. Diagnosing conditions earlier and regularly tracking disease progression gives eyecare professionals an immense advantage in caring for their patients’ vision. Trefethen About Radius XR – RadiusXR The Radius XR platform is a portable vision diagnostic and patient engagement system that combines medical-grade diagnostics, business management, and patient education tools in a single wearable AR/VR device. The RadiusExam® proprietary algorithm provides diagnostic testing results equivalent to current exam gold standards, with the clinical science validated by Deming regression. As the algorithm presents stimuli to patients, Radius Adaptive® responds to maximize the algorithm's speed. The total hardware and software system helps medical professionals diagnose patients with accuracy, grow their eyecare practices, enhance patient engagement, and reduce staff workload by enabling patients to perform self-guided vision exams with minimal supervision. Radius XR builds on the therapeutic legacy of IrisVision, the first clinically validated wearable low vision solution. IrisVision was backed by a research grant from the National Eye Institute and developed in collaboration with researchers from top ophthalmology centers at Johns Hopkins University, Stanford University, and UPMC Pittsburg.

Read More


Henry Ford Health and the PINC AI™ Applied Sciences Team Lead Action to Advance Health Equity

Henry Ford Health | November 21, 2022

Henry Ford Innovations one of the nation's leading healthcare innovation programs, recently hosted the inaugural "Advancing Health Equity Through Innovation and Collaboration" event in partnership with the PINC AI™ Applied Sciences team, a leading provider of advanced analytics, technology solutions and clinical research support services to the life sciences industry. The initiative's purpose was to turn health equity conversations into action by taking measurable steps towards improving the health of millions. Participants included global leaders in life sciences, as well as Henry Ford Health innovators who are already implementing programs to address health disparities in groups who have been historically marginalized and underrepresented. "Part of innovating is looking for partners to expand successful test programs and develop new ones. Partnerships like the ones we're forging with these corporate partners will create a true impact in addressing health equity. We are thrilled to have the opportunity to share our findings with national leaders in the life sciences and pharmaceutical industries and chart a path forward to bring these solutions to help more people." Lisa Prasad, Henry Ford Health's Chief Innovation Officer and leader of Henry Ford Innovations The two-day event in late October included a presentation of case studies from successful Henry Ford Health programs, including community-based partnerships to increase health screenings. That program found that a lack of trust in institutions can deter people from getting preventative care and that using community partners for healthcare services can reduce barriers and increase access to care. Other case studies covered programs to improve hypertension in young African American men and reduce infant mortality among underserved populations. The unique action-focused event allowed leaders from Henry Ford Health, the PINC AI™ Applied Sciences team and collaborators from eight global life sciences companies to meet, connect and work together on ways to amplify and expand pilot programs. "The impactful work Henry Ford Health already has under way makes Detroit an ideal location to look for solutions to reduce health inequities across the country," said Denise Juliano, Life Sciences Group Vice President, PINC AI™ Applied Sciences. "PINC AI™ Applied Sciences partners with leaders in healthcare to improve health outcomes and advance equitable care for all people. This initiative was a great step forward to accelerate our efforts to address the challenges of health inequities that continue to persist." Because of Henry Ford Health's community connections and its long-standing work to improve diversity, equity, inclusion and justice (DEIJ), the health system is a leader in researching and tackling health disparities in Detroit. In 2021, Henry Ford launched a new initiative to improve the representation of African American people in cancer clinical trials. It was an important collaboration, especially considering that recent research shows 85 percent of participants in clinical trials are white. Another program supported by HFI provides medical mentorship and internship opportunities for Detroit-based high school students. Both initiatives serve as examples of the meaningful change health and life sciences organizations can affect together. "This initiative is an example of how Henry Ford's commitment to DEIJ extends beyond ideas and connects directly to action," said Ikenna Okereke, M.D., Henry Ford Health's Vice Chair of Surgery and Director of Thoracic Surgery. "Through Henry Ford's Department of Surgery High School Mentorship Program, I've seen firsthand how programs that work in other communities can grow for a larger impact. I'm excited to be a part of the next chapter in creating more programs and initiatives to address health disparities." Henry Ford Health and the PINC AI™ Applied Sciences team will now work with the summit's participating partners to strengthen and scale solutions to advance health equity. About Henry Ford Health Serving communities across Michigan and beyond, Henry Ford Health is committed to partnering with patients and members along their entire health journey. Henry Ford Health provides a full continuum of services – from primary and preventative care, to complex and specialty care, health insurance, a full suite of home health offerings, virtual care, pharmacy, eye care and other healthcare retail. It is one of the nation's leading academic medical centers, recognized for clinical excellence in cancer care, cardiology and cardiovascular surgery, neurology and neurosurgery, orthopedics and sports medicine, and multi-organ transplants. Consistently ranked among the top five National Institutes of Health (NIH)-funded institutions in Michigan, Henry Ford Health engages in more than 2,000 research projects annually. Equally committed to educating the next generation of health professionals, Henry Ford Health trains more than 4,000 medical students, residents, and fellows every year across 50+ accredited programs. With more than 33,000 valued team members, Henry Ford Health is also among Michigan's largest and most diverse employers, including nearly 6,000 physicians and researchers from the Henry Ford Medical Group, Henry Ford Physician Network and Jackson Health Network. The health system is led by President and CEO Robert G. Riney and serves a growing number of customers across 250+ locations throughout Michigan including five acute care hospitals, two destination facilities for complex cancer and orthopedics and sports medicine care, three behavioral health facilities, primary care and urgent care centers. About the PINC AI™ Platform PINC AI™ is the technology and services platform of Premier Inc. With more than 20 years' worth of cost, quality and operational data gleaned from 45 percent of U.S. hospital discharges, 812 million hospital outpatient and clinic encounters and 131 million physician office visits, the PINC AI™ platform provides actionable intelligence to help improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI™ offerings rely on advanced analytics to identify improvement opportunities, consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change. The PINC AI™ platform is also the data engine powering Premier's newest brands – Remitra™ and Contigo Health®.

Read More


GE Healthcare Introduces Omni Legend: A First-of-its-Kind All-Digital PET/CT System to Drive Efficiency, Enhance Diagnostics

GE Healthcare | October 17, 2022

At the European Association of Nuclear Medicine Annual Meeting, GE Healthcare proudly introduces Omni Legendi, the first system on its all-new, all-digital PET/CT platform. This cutting-edge system features a brand-new category of digital BGO detector material with a small crystal size that delivers more than two times the sensitivity of prior digital scannersii, enabling faster total scan timesiii and impressive small lesion detectabilityiv. It is designed to improve operational efficiency, enhance the patient experience, and increase diagnostic power, ideally helping to enable improved patient outcomes. Additionally, the system’s theranosticsv capabilities and ability to image short life tracers, as well as dynamic protocolsvi, help empower clinicians with greater clinical information across more oncology, cardiology, and neurology procedure types than ever before. “Sensitivity and image quality are everything in PET/CT,” explains John Kennedy, Ph.D., Chief Physicist, Nuclear Medicine Department, Rambam Health Care Campus, and Lecturer at Technion – Israel Institute of Technologyvii. “Omni Legend delivers on both – meeting all our image quality criteria for oncology and providing impressive sensitivity to image high count tracers for cardiac and neuro imaging, which helps better inform patient diagnoses and monitoring. Also, we have been able to increase patient throughput by more than a third thanks to the system’s fast total scan times – even achieving 35 patient scans in a 9.5-hour shift – and reduce dose by 40% versus the previous equipment that was installed. This not only enables better patient access and experience but also allows us to increase overall hospital efficiencyviii.” As the pace of change in healthcare continues to increase, health plan leaders cite managing costs and driving operational efficiency as the top two challenges they face todayix. This is consistent with comments by global Molecular Imaging departments, which note operational efficiency as a top barrier to growing PET/CT procedure volumesx. Omni Legend is GE Healthcare’s response to these growing challenges, helping healthcare systems overcome today’s barriers with a collection of intuitive workflow solutions enhanced by artificial intelligence (AI), including its new Precision DLi solution for deep learning image processing in PET/CT as well as its AI-based Auto Positioning Camera. “Having access to high-quality images to determine patient care is foundational to administering quality healthcare,” adds Prof. Zohar Keidar, Director of Nuclear Medicine & the PET/CT Department at Rambam and an Associate Clinical Professor at the Technion Faculty of Medicinevii. “With this in mind, a department like ours – which has a very heavy workload – requires a system that enables flexibility for emergency cases, in addition to our already packed schedules. Omni Legend provides that flexibility. Within a few short weeks/months, we were able to increase our number of scans by 150 percent – going from 30 to 45 patient scans per day. We used to have a long wait list; but today, if something is urgent, we can quickly scan a patient while keeping our other scheduled appointmentsviii. And the system’s clinical protocols afford us additional flexibility, allowing us to stage patients on any scanner, regardless of the system the patients was previously scanned on – affording us new opportunities in fleet management.” More than a new processing technique, Precision DLi is engineered using Deep Learning with a sophisticated deep neural network trained on thousands of images created with different reconstruction methods. It was designed to provide the image quality performance benefits most associated with hardware-based Time-of-Flight, such as better contrast-to-noise ratio, contrast recovery, and quantitative accuracy. The capabilities of Omni Legend are further elevated by the inclusion of Q.Clear (BSREM), GE Healthcare’s pioneering PET image reconstruction technology, and MotionFree, the company’s proven, deviceless respiratory motion correction technology. Q.Clear helps to ensure reliable quantification, while MotionFree operates seamlessly in the background to correct respiratory motion artifacts for all patient types. Furthermore, the new system’s operational efficiency solutions help improve the PET/CT imaging experience for both the technologist and the patient with convenient features that provide A fast data quality assurance process that saves time with streamlined calibration; Simplified protocol selection on the gantry touchscreen and a new user interface to enable an easy PET/CT process from start to finish; and Enhanced patient positioning capabilities as a result of AI-based Auto Positioning that automatically centers the patient for a completely hands-free positioning experience. This streamlined patient setup frees up technologists to focus on making patients feel more comfortable. Omni Legend also features LED ambient lighting to encourage a calming mood as well as a graphic pattern for the patient to view in the system to help in both alleviating stress and reducing movement for nervous patients. “We built our scalable Omni platform from the ground up to meet the needs of our customers and their patients today and in the future. With the patient in mind, we leaned on our longstanding technological leadership and strong clinical collaborations to enhance the scan experience with entirely new components designed to help improve clinical outcomes. The result is an all-digital detector, a cutting-edge deep learning solution, and workflow enhancements to help enable more personalized care.” Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE Healthcare Omni Legend was designed with theranostics in mind, enabling clinicians to reach new levels of sensitivity and detectability for incredibly clear images. Already, the system boasts the highest sensitivity per cm in the marketxi and images Gallium 68 for diagnosis, staging, or restaging. Future-ready capabilities include a multi-directional, upgradable platform that can potentially expand in each of the core dimensions of PET/CT imaging, including axial field-of-view, digital detector technology, software, CT capabilities, and imaging of new tracers. About GE Healthcare GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Read More